Table 3.

Fatty acid composition of red blood cell choline phosphoglycerides of HU-untreated (n = 17) and treated (n = 19) HbSS patients and HbAA controls (n = 20).

Fatty acids	HbSS (untreated)	HbSS (treated)	HbAA (healthy control)
16:0 (Palmitic acid)	36.7 ± 1.6	36.3 ± 1.7×××	31.8 ± 2.5+++
18:0 (Stearic acid)	8.9 ± 0.7***	10.3 ± 1.2×××	13.2 ± 1.0+++
20:0 (Arachidic acid)	0.1 ± 0.03***	0.2 ± 0.1×	0.1 ± 0.1
22:0 (Behenic acid)	tr.	tr.	tr.
24:0 (Lignoceric acid)	0.04 ± 0.01	0.05 ± 0.01	.04 ± 0.01
∑saturates	46.0 ± 1.3**	47.2 ± 0.8××	45.2 ± 1.9
16:1n-7 (Palmitoleic acid)	0.3 ± 0.1	0.3 ± 0.1	0.3 ± 0.1
18:1n-7 (Vaccenic acid)	1.6 ± 0.2	1.7 ± 0.3×	1.4 ± 0.2+
18:1n-9 (Oleic acid)	18.3 ± 1.1	17.7 ± 1.5×××	14.2 ± 1.5+++
24:1n-9 (Nervonic acid)	tr.	tr.	tr.
∑monoenes	20.2 ± 1.1	19.7 ± 1.6×××	15.9 ± 1.6+++
18:2n-6 (Linoleic acid)	16.3 ± 1.4	15.4 ± 2.6×××	20.7 ± 2.1+++
18:3n-6 (γ-linolenic acid)	0.1 ± 0.02***	0.1 ± 0.03	0.1 ± 0.05
20:2n-6 (Eicosadienoic acid)	0.5 ± 0.1	0.4 ± 0.2	0.5 ± 0.1
20:3n-6 (Dihomo-γ-linolenic)	1.9 ± 0.4	1.7 ± 0.2××	2.1 ± 0.1
20:4n-6 (Arachidonic acid)	9.6 ± 0.7	9.5 ± 1.1	9.4 ± 1.5
22:4n-6 (Adrenic acid)	0.9 ± 0.2	0.9 ± 0.2×××	0.7 ± 0.1+++
22:5n-6 (Osbond acid)	0.5 ± 0.1	0.5 ± 0.1×	0.6 ± 0.2+
∑metabolites	13.6 ± 0.7	13.1 ± 1.3	13.4 ± 1.7
∑n-6	29.9 ± 1.6	28.4 ± 1.9×××	34.1 ± 2.7
18:3n-3 (α-Linolenic acid)	tr.	tr.	tr.
20:5n-3 (Timnodonic acid)	0.1 ± 0.02	0.1 ± 0.05	0.11 ± 0.03
22:5n-3 (Clupanodonic acid)	0.3 ± 0.06	0.3 ± 0.07	0.3 ± 0.05
22:6n-3 (Cervonic acid)	0.7 ± 0.2	0.8 ± 0.4	1.0 ± 0.2++
∑metabolites	1.1 ± 0.2	1.2 ± 0.4	1.3 ± 0.3++
∑n-3	1.2 ± 0.2	1.2 ± 0.4	1.4 ± 0.3+
N6/N3	26.58 ± 5.03	24.91 ± 6.78	25.65 ± 5.09

tr.: trace.

HU-untreated versus treated HbSS patients, *P < 0.05, **P < 0.01, ***P < 0.001.

HU-untreated HbSS patients versus HbAA healthy controls, ⁺ P < 0.05, ⁺⁺ P < 0.01, ⁺⁺⁺ P < 0.001.

HU-treated HbSS patients versus HbAA healthy controls, ^× P < 0.05, ^×× P < 0.01, ^××× P < 0.001.